Bright Minds Biosciences (TSE:DRUG) has released an update.
Bright Minds Biosciences has launched the Phase 2 BREAKTHROUGH Study to assess its novel drug BMB-101 for treating drug-resistant epilepsy disorders, specifically Absence Epilepsy and Developmental Epileptic Encephalopathy. The study aims to enroll 20 adults and will test the safety, tolerability, and efficacy of the drug, which offers a new mechanism of action for long-term treatment.
For further insights into TSE:DRUG stock, check out TipRanks’ Stock Analysis page.
